Ignite Creation Date:
2024-05-06 @ 6:21 PM
Last Modification Date:
2024-10-26 @ 2:46 PM
Study NCT ID:
NCT05638867
Status:
RECRUITING
Last Update Posted:
2024-01-17
First Post:
2022-11-26
Brief Title:
NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
Sponsor:
China National Center for Cardiovascular Diseases
Organization:
China National Center for Cardiovascular Diseases
Study Overview
Official Title:
A Randomized Controlled Clinical Trial of PARIS Coronary Thrombosis Risk Score Combined With D-dimer to Guide New Oral Anticoagulant Antithrombotic Therapy in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to compare short-term Triple Antithrombotic Therapy DAPT Rivaroxaban followed by DAPT with standard DAPT in selected ACS patients with high ischemic risk The main questions it aims to answer are
Whether the intervention is effective in reducing ischemic events
Whether the intervention is safe from increasing bleeding events especially severe or fatal ones
Participants will be randomized to receive standard DAPT therapy for the entire study duration or low-dose rivaroxabanDAPT for 3 months followed by standard DAPT for the rest of the study duration Patients enrolled should complete 5 follow-ups in the form of clinic visit or telephone call
Whether the intervention is effective in reducing ischemic events
Whether the intervention is safe from increasing bleeding events especially severe or fatal ones
Participants will be randomized to receive standard DAPT therapy for the entire study duration or low-dose rivaroxabanDAPT for 3 months followed by standard DAPT for the rest of the study duration Patients enrolled should complete 5 follow-ups in the form of clinic visit or telephone call
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None